Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:availability |
not commercially available
|
| gptkbp:avionics |
synthesized for comparison
|
| gptkbp:built |
requires further optimization
|
| gptkbp:chemicalFormula |
stable under normal conditions
small molecule contains thiazole ring C20H22N2O2S reacts with electrophiles developed for enhanced efficacy interacts with proteins moderately stable performed using spectroscopy requires thorough evaluation arylacetamides |
| gptkbp:clinicalTrials |
ongoing
being explored |
| gptkbp:collaborations |
various research institutions
with academic institutions with pharmaceutical companies |
| gptkbp:compatibleWith |
inhibitor of certain kinases
exhibits cytotoxicity |
| gptkbp:composedOf |
multi-step organic synthesis
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:established |
scientists_at_the_University_of_California
|
| gptkbp:firstClaim |
therapeutic agent
|
| gptkbp:funding |
grants from health organizations
secured for further studies |
| gptkbp:future_plans |
preclinical
clinical development plans |
| https://www.w3.org/2000/01/rdf-schema#label |
SR 745
|
| gptkbp:impact |
not fully characterized
|
| gptkbp:is_aimed_at |
various cancers
|
| gptkbp:is_used_in |
research on cancer
|
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:market |
oncology therapeutics
|
| gptkbp:notableWork |
significant in cancer research
|
| gptkbp:origin |
N-(4-(4-(dimethylamino)phenyl)thiazol-2-yl)-2-(4-methylphenyl)acetamide
|
| gptkbp:patentAssignee |
gptkb:University_of_California
|
| gptkbp:patentStatus |
patented
|
| gptkbp:publications |
multiple peer-reviewed articles
|
| gptkbp:regulatoryCompliance |
not yet approved
|
| gptkbp:related_to |
thiazole derivatives
|
| gptkbp:research |
growing interest
promising results in vitro |
| gptkbp:research_areas |
pharmacology
ongoing in various labs |
| gptkbp:research_focus |
high in oncology research.
targeting tumor growth understanding its mechanism |
| gptkbp:safety_features |
under investigation
|
| gptkbp:safetyFeatures |
required before human trials
|
| gptkbp:targets |
cancer cells
|
| gptkbp:triggerType |
inhibits specific signaling pathways
|
| gptkbp:weight |
350.47 g/mol
|